# CVRx Q3 2026 Earnings Report Highlights

> CVRx reports 6.1% revenue drop as Medicare reimbursement delays and physician turnover challenge growth.
- Title: CVRx Q3 2026 Earnings Report Highlights · The Motley Fool
- Summary: CVRx reports 6.1% revenue drop as Medicare reimbursement delays and physician turnover challenge growth.
- Keywords: cvrx, q3 2026, revenue, medicare, physician turnover, heart failure, barostim, reimbursement delays, full year revenue guidance, operating expenses, The Motley Fool
- Source: The Motley Fool — https://fool.com/earnings/call-transcripts/2026/11/06/cvrx-cvrx-q3-2026-earnings-call-transcript
- Author: Motley Fool Transcribing
- Published: 2026-11-06T15:43:43+00:00
- Read time: 1 min
- Topics: cvrx, q3 2026, revenue, medicare, physician turnover, heart failure, barostim, reimbursement delays, full year revenue guidance, operating expenses, finance, money
## Q3 Revenue
Total revenue of $13.8 million, a 6.1% decrease compared to Q3 2025.
## U.S. Revenue
U.S. revenue of $13 million, a 4% decline year over year.
## European Revenue
European revenue of $900,000, a 27% decline year over year.
## U.S. Commercial Units
412 U.S. commercial units, down from 420 units in Q3 2025.
## Gross Margin
Gross margin of 87%, consistent with 2025.
## Active Implant Centers
262 U.S. active implant centers as of Sept. 30, 2026.
## Medicare Approval Rate
51% Medicare Advantage approval rate for 30-day prior authorizations.
## Largest Payer Approval Rate
12% approval rate for 30-day prior authorizations with largest Medicare Advantage payer.
## R&D Expenses
R&D expenses of $2.7 million, a 16% decrease.
## Selling, General and Administrative Expenses
SG&A expenses of $22.4 million, a 2% increase.
## Operating Expenses
Operating expenses of $25.1 million for the quarter.
## Net Loss
Net loss of $14.2 million, or $0.52 per share.
## Cash and Cash Equivalents
Cash and cash equivalents of $58.7 million as of Sept. 30, 2026.
## Full Year 2026 Revenue Guidance
Full year 2026 revenue guidance of $56 million to $57 million.
## Fourth Quarter 2026 Revenue Guidance
Fourth quarter 2026 revenue guidance of $11.7 million to $12.7 million.
## Cash Runway
Cash runway of at least 18 months.
## Key takeaway

CVRx reported $13.8 million Q3 revenue, a 6.1% year-over-year decline, driven by Medicare reimbursement delays and physician turnover, with full-year revenue guidance lowered to $56-$57 million.